Actively Recruiting
The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After Stroke
Led by University of Calgary · Updated on 2024-07-09
120
Participants Needed
6
Research Sites
167 weeks
Total Duration
On this page
Sponsors
U
University of Calgary
Lead Sponsor
U
University Health Network, Toronto
Collaborating Sponsor
AI-Summary
What this Trial Is About
The CAMAROS trial is a randomized controlled phase II trial analyzing the effect of coupling a C-C chemokine receptor 5 (CCR5) antagonist, Maraviroc (Celsentri), and exercise to improve both upper and lower extremity recovery after a stroke.
CONDITIONS
Official Title
The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After Stroke
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Primary ischemic anterior circulation stroke
- Age 18 years or older
- Stroke occurred at least 5 days ago but within 8 weeks before starting medication
- Hemiparesis requiring inpatient rehabilitation
- Assistance available for daily rehabilitation practice and transportation
- Adequate language skills to understand consent and therapy information
- At least some shoulder movement with gravity eliminated and finger extension in two or more digits, or visible hip flexion or extension
- Upper Extremity subgroup: Medical Research Council grade >1 for shoulder abduction and finger extensor on at least two digits, and Upper Extremity Fugl-Meyer Assessment Score ≤56
- Lower Extremity subgroup: requiring 2-person assist and walking speed less than 0.8 m/s
You will not qualify if you...
- Modified Rankin score of 2 or more before stroke
- Illness or lack of resources preventing return to living outside a facility
- History of dementia
- History of hepatitis or elevated liver enzymes
- History of kidney insufficiency or creatinine clearance under 60 mL/min/1.73m2
- Cancer or chronic illness limiting 1-year survival or ability to exercise
- Serious disabling pre-stroke disease such as Parkinson's, severe brain injury, or amputation
- Seizure related to stroke or epilepsy
- Current use of carbamazepine, phenobarbital, or phenytoin
- Pregnancy or breastfeeding, or positive pregnancy test at baseline
- Women of childbearing potential not using highly effective contraception
- Known HIV positive status
- Current use of specific antifungal or antibacterial medications (ketoconazole, itraconazole, voriconazole, rifampin, clarithromycin, rifabutin with protease inhibitor)
- Current use of St. John's Wort
- Current use of Paxlovid
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
University of Calgary & Foothills Medical Centre
Calgary, Alberta, Canada, T2N 2T9
Actively Recruiting
2
University of British Columbia & GF Strong Rehabilitation Centre
Vancouver, British Columbia, Canada, V5Z 2G9
Actively Recruiting
3
Dalhousie University
Halifax, Nova Scotia, Canada, B3H 3J5
Actively Recruiting
4
Parkwood Institute
London, Ontario, Canada, N6C 0A7
Actively Recruiting
5
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
Not Yet Recruiting
6
Toronto Rehabilitation Institute - University Health Network
Toronto, Ontario, Canada, M5G 2A2
Not Yet Recruiting
Research Team
A
Alexandra McKinnon
CONTACT
M
Mark Piitz
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here